Breast Cancer Trial, Recruiting (NCT04638725)

Breast Cancer Trial, Recruiting NCT04638725 Sponsor: Centre Paul Strauss Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04638725 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years old or older
You have been diagnosed with a specific type of breast cancer (breast adenocarcinoma) that has not spread to other parts of the body and can be treated with surgery
You are currently receiving, or have previously received, at least one treatment that targets the HER2 protein as part of your breast cancer treatment (either before or after surgery)
You are covered by a national or local social security/health insurance scheme
You are willing and able to give written consent to take part
Your chemotherapy treatment (before or after surgery) started on or after 01 January 2019
You may still be eligible if you received HER2-targeting treatments (such as trastuzumab, pertuzumab, neratinib, or T-DM1) as part of another clinical trial

Who may not be able to join:

You are unable to attend or participate in the study's required assessments due to where you live, your personal situation, or your mental health (confirm with trial site)
You are under a court-ordered legal protection, guardianship, or supervision arrangement
You had another cancer at any point in the 5 years before starting your HER2-targeting treatment
You currently have another cancer at the same time, unless it is a separate, non-spreading cancer that has been treated with surgery only

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 2 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04638725

Sponsor: Centre Paul Strauss

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

More information: https://clinicaltrials.gov/study/NCT04638725

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years old or older
You have been diagnosed with a specific type of breast cancer (breast adenocarcinoma) that has not spread to other parts of the body and can be treated with surgery
You are currently receiving, or have previously received, at least one treatment that targets the HER2 protein as part of your breast cancer treatment (either before or after surgery)
You are covered by a national or local social security/health insurance scheme
You are willing and able to give written consent to take part
Your chemotherapy treatment (before or after surgery) started on or after 01 January 2019
You may still be eligible if you received HER2-targeting treatments (such as trastuzumab, pertuzumab, neratinib, or T-DM1) as part of another clinical trial

Who may not be able to join:

You are unable to attend or participate in the study's required assessments due to where you live, your personal situation, or your mental health (confirm with trial site)
You are under a court-ordered legal protection, guardianship, or supervision arrangement
You had another cancer at any point in the 5 years before starting your HER2-targeting treatment
You currently have another cancer at the same time, unless it is a separate, non-spreading cancer that has been treated with surgery only

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 2 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Centre Paul Strauss

Registry

ClinicalTrials.gov

Start date

15 December 2021

Est. completion

15 December 2033

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Pathologic Complete Response (pCR); Disease Free Survival (DFS); Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov